Population-based study of the incidence and survival for intraductal carcinoma of the prostate

Dinerman, Brian; Khani, Francesca; Golan, Ron; Bernstein, Adrien; Cosiano, Michael F.; Margolis, Daniel; Hu, Jim C.

doi:10.1016/j.urolonc.2017.08.015

Cited by 29 publications

(26 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Limitations to this study are the retrospective nature and that there may also be under-reporting of IDC-P as indicated by the slightly lower incidence compared to other published data. 28 There may also be a selection bias as this study's cohort consisted of mainly white Caucasian males from a single country. In addition, there is no formal genetic counseling or screening pathway for patients with IDC-P in Ireland and the familial link described herein must be taken on the merit of the phone interviews with patients with IDC-P.…”

Section: Discussionmentioning

confidence: 99%

Intraductal carcinoma of the prostate in an Irish prostate cancer patient cohort—an aggressive pathology and a strong familial link

Haroon

O'Grady-Coyne

Davis

et al. 2020

Prostate International

View full text Add to dashboard Cite

Background The prevalence of intraductal carcinoma of the prostate (IDC-P) is poorly studied in the Irish population. This study investigated the incidence and clinicopathologic characteristics of IDC-P in an Irish prostate cancer (PCa) patient cohort. The study also discusses the rationale for genetic counseling and screening in Irish patients with familial risk factors for IDC-P. Materials and methods This study investigated patients diagnosed with IDC-P on prostate biopsy from 2012 to 2016. Primary outcome measurements were incidence, management, and clinical outcomes after follow-up in patients with IDC-P. The secondary outcome measurement was to identify a familial link for IDC-P. Results A total of 1,143 patients were diagnosed with PCa on needle biopsy, of which 30 (2.3%) had concomitant IDC-P. Mean age and prostate-specific antigen at diagnosis were 68.6 ± 10.5 years (range 53–85 years) and 9.15 ± 8.65 ng/mL (range 2.1–166 ng/mL), respectively. In total, 17 of 30 patients (57%) were diagnosed with concomitant high-grade (i.e., ≥Gleason score 8) PCa. Eight patients (27%) were treated with radical prostatectomy; of which five had biochemical recurrence (BCR) after 10.55 ± 25.9 months. Eleven patients (37%) received radical radiotherapy; of which one had BCR after 36 months. Eleven patients (37%) presented with advanced PCa and were managed with androgen deprivation therapy ± chemotherapy. A family history for PCa in first-degree relatives was found in eight patients (27%). Conclusions IDC-P is associated with more aggressive clinicopathologic features and an increased risk of BCR after treatment. In Ireland, clinical guidelines and a genetic screening pathway are required to provide early detection and appropriate multimodal management of patients with IDC-P.

show abstract

Section: Discussionmentioning

confidence: 99%

Intraductal carcinoma of the prostate in an Irish prostate cancer patient cohort—an aggressive pathology and a strong familial link

Haroon

O'Grady-Coyne

Davis

et al. 2020

Prostate International

View full text Add to dashboard Cite

show abstract

“…As the adverse clinical outcomes based on the presence of IDC-P in primary prostate cancer is established, the revised guidelines on pathology reporting recommend standard reporting of IDC-P [8][9][10][11]. Pathologists broadly refer to two biologically distinct diseases.…”

Section: Discussionmentioning

confidence: 99%

Influence of Intra-ductal Carcinoma on Clinical Outcomes in Men with Prostate Cancer: Systematic Review and Meta-analysis

Kumar¹,

Alam²,

Tanneru³

et al. 2020

Glob J Cancer Ther

View full text Add to dashboard Cite

Purpose: To provide a comprehensive summary of published literature regarding infl uence of intraductal carcinoma of prostate (IDC-P) on clinical outcomes in men with Prostate Cancer (PC). Methods: We compared the following clinical endpoints in men with PC with or without IDC-P; Castration Resistant Free Survival (CFS) and Overall Survival (OS) for metastatic PC (Group 1), biochemical recurrence rate (BR) and/or cancer specifi c survival (CSS) in men undergoing radical prostatectomy (Group 2a) or radiotherapy (Group 2b). A meta-analysis was done by fi xed effect model using 12 studies reporting Hazard Ratio (HR) and meeting the selection criteria.

show abstract

“…It also does not respond to treatment in the same fashion as usual PC without IDC-P. In low-grade organ-confined PC, IDC-P has been associated with a high risk of progression [11]. Yet, to our knowledge, no treatment response studies exist for IDC-P in non-metastatic PC, even though it often progresses towards early distant metastases and reduced survival [12].…”

Section: Introductionmentioning

confidence: 99%

Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate

et al. 2019

View full text Add to dashboard Cite

Background Intraductal carcinoma of the prostate (IDC-P) is an independent biomarker of recurrence and survival with particular treatment response, yet no study has tested its response to radiotherapy. The aim of our project was to test the impact of adjuvant radiotherapy (ART) in patients with localized to locally advanced prostate cancer (PC) and IDC-P. Materials and methods We performed a retrospective study of men with pT2-T3 PC treated by radical prostatectomy (RP) with or without ART, from two centres (1993–2015). Exclusion criteria were the use of another type of treatment prior to biochemical recurrence (BCR), and detectable prostate- specific antigen (PSA) following RP or ART. Primary outcome was BCR (2 consecutive PSA ≥ 0.2 ng/ml). Patients were grouped by treatment (RP only /RP + ART), IDC-P status, and presence of high-risk features (HRF: Grade Groups 4–5, positive margins, pT3 stage). Results We reviewed 293 RP specimens (median follow-up 99 months, 69 BCR). Forty-eight patients (16.4%) were treated by RP + ART. Multivariate Cox regression for BCR indicated that IDC-P had the strongest impact (hazard ratio [HR] = 2.39, 95% confidence interval [CI]:1.44–3.97), while ART reduced the risk of BCR (HR = 0.38, 95%CI: 0.17–0.85). Other HRF were all significant except for pT3b stage. IDC-P[+] patients who did not receive ART had the worst BCR-free survival (log-rank P = 0.023). Furthermore, IDC-P had the same impact on BCR-free survival as ≥1 HRF (log-rank P = 0.955). Conclusion Men with IDC-P who did not receive ART had the highest BCR rates, and IDC-P had the same impact as ≥1 HRF, which are often used as ART indications. Once validated, ART should be considered in patients with IDC-P. Electronic supplementary material The online version of this article (10.1186/s13014-019-1267-3) contains supplementary material, which is available to authorized users.

show abstract

Population-based study of the incidence and survival for intraductal carcinoma of the prostate

Cited by 29 publications

References 30 publications

Intraductal carcinoma of the prostate in an Irish prostate cancer patient cohort—an aggressive pathology and a strong familial link

Intraductal carcinoma of the prostate in an Irish prostate cancer patient cohort—an aggressive pathology and a strong familial link

Influence of Intra-ductal Carcinoma on Clinical Outcomes in Men with Prostate Cancer: Systematic Review and Meta-analysis

Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate

Contact Info

Product

Resources

About